Humanigen, Inc. announced it plans to support a Phase II/III study to evaluate lenzilumab for the early treatment of acute graft versus host disease following allogeneic hematopoietic stem cell transplantation in collaboration with IMPACT.
[Humanigen, Inc.]
Sorry, but the selected Zotpress account can't be found.
